{"transactions":[{"id":732835,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":37006,"kind":"person","name":"Sabba Stephen L","position":1,"cik":"0001442372","reported_name":"Sabba Stephen L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-06-18T12:37:48.000Z","date":"2026-06-16","kind":"exercise","planned":false,"acquired":false,"shares":2145,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"These securities, as represented in Column 5, were acquired by a grant of 2,456 shares approved by the Board of Directors of the Company at the 2017 Meeting, as previously reported on the Reporting Person's Form 4, dated 30 May 2017. That grant vested in full on the first anniversary of the grant date or immediately (x) upon a change in control or a hostile takeover of the Company or (y) the death or permanent disability of the grantee if still serving at that time. The original grant was adjusted to 2,145 shares and the exercise price adjusted to $66.13 pursuant to the OmniAb Inc. separation from the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These securities, as represented in Column 5, were acquired by a grant of 2,456 shares approved by the Board of Directors of the Company at the 2017 Meeting, as previously reported on the Reporting Person's Form 4, dated 30 May 2017. That grant vested in full on the first anniversary of the grant date or immediately (x) upon a change in control or a hostile takeover of the Company or (y) the death or permanent disability of the grantee if still serving at that time. The original grant was adjusted to 2,145 shares and the exercise price adjusted to $66.13 pursuant to the OmniAb Inc. separation from the Company."}],"balance_after":0,"derivative":{"exercise_price":66.13,"expiration_date":"2027-05-25","underlying":"Common Stock","underlying_shares":2145},"source":{"system":"sec-edgar","filing":"0001104659-26-075456","document":"tm2618247-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/886163/000110465926075456/tm2618247-1_4seq1.xml","form_type":"4"}},{"id":732834,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":37006,"kind":"person","name":"Sabba Stephen L","position":1,"cik":"0001442372","reported_name":"Sabba Stephen L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-18T12:37:48.000Z","date":"2026-06-16","kind":"sale","planned":false,"acquired":false,"shares":2145,"price":254,"value":544830.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These securities, as represented in Column 5, include the grant of 836 restricted shares approved by the Board of Directors of the Company at the 2026 Meeting held 5 June 2026, which shares were previously reported on a Form 4 for this Reporting Person dated 9 June 2026."}],"balance_after":33629,"source":{"system":"sec-edgar","filing":"0001104659-26-075456","document":"tm2618247-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000110465926075456/tm2618247-1_4seq1.xml","form_type":"4"}},{"id":732833,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":37006,"kind":"person","name":"Sabba Stephen L","position":1,"cik":"0001442372","reported_name":"Sabba Stephen L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-18T12:37:48.000Z","date":"2026-06-16","kind":"exercise","planned":false,"acquired":true,"shares":2145,"price":66.13,"value":141848.85,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These securities, as represented in Column 5, include the grant of 836 restricted shares approved by the Board of Directors of the Company at the 2026 Meeting held 5 June 2026, which shares were previously reported on a Form 4 for this Reporting Person dated 9 June 2026."}],"balance_after":35774,"source":{"system":"sec-edgar","filing":"0001104659-26-075456","document":"tm2618247-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000110465926075456/tm2618247-1_4seq1.xml","form_type":"4"}},{"id":745419,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":37006,"kind":"person","name":"Sabba Stephen L","position":1,"cik":"0001442372","reported_name":"Sabba Stephen L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-06-09T23:41:48.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":2938,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant."}],"balance_after":2938,"derivative":{"exercise_price":237,"expiration_date":"2036-06-05","underlying":"Common Stock","underlying_shares":2938},"source":{"system":"sec-edgar","filing":"0002001011-26-000100","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000100/edgardoc.xml","form_type":"4"}},{"id":745418,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":37006,"kind":"person","name":"Sabba Stephen L","position":1,"cik":"0001442372","reported_name":"Sabba Stephen L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-09T23:41:48.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":836,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant."}],"balance_after":33629,"source":{"system":"sec-edgar","filing":"0002001011-26-000100","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101126000100/edgardoc.xml","form_type":"4"}},{"id":828670,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":37006,"kind":"person","name":"Sabba Stephen L","position":1,"cik":"0001442372","reported_name":"Sabba Stephen L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-25T15:13:39.000Z","date":"2026-03-23","kind":"sale","planned":false,"acquired":false,"shares":1000,"price":207.8727,"value":207872.7,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These securities, as represented in Column 5, include a grant of 1,209 restricted shares approved by the Board of Directors of the Company at the 2025 Meeting held 6 June 2025, which shares were previously reported on a Form 4 for this Reporting Person dated 10 June 2025, and are included on this Form 4 only to report that they will vest in full within six (6) months from the date hereof."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price, as represented in Column 4, represents an average price per share of the following transactions on 23 March 2026: 100 shares at $208.055000, 17 shares at $207.980000, and 883 shares at $207.850000."}],"balance_after":32793,"source":{"system":"sec-edgar","filing":"0001104659-26-034308","document":"tm269702-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000110465926034308/tm269702-1_4seq1.xml","form_type":"4"}},{"id":859683,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":37006,"kind":"person","name":"Sabba Stephen L","position":1,"cik":"0001442372","reported_name":"Sabba Stephen L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non- Qualified Stock Option (right to buy)","published_at":"2026-03-05T16:05:17.000Z","date":"2026-03-03","kind":"exercise","planned":false,"acquired":false,"shares":2034,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"These securities, as represented in Column 5, were acquired by a grant of 2,329 shares approved by the Board of Directors of the Company at the 2016 Meeting, as previously reported on the Reporting Person's Form 4, dated 25 May 2016. That grant vested in full on the first anniversary of the grant date or immediately (x) upon a change in control or a hostile takeover of the Company or (y) the death or permanent disability of the grantee if still serving at that time. The original grant was adjusted to 2,034 shares and the exercise price adjusted to $69.51 pursuant to the OmniAb Inc. separation from the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These securities, as represented in Column 5, were acquired by a grant of 2,329 shares approved by the Board of Directors of the Company at the 2016 Meeting, as previously reported on the Reporting Person's Form 4, dated 25 May 2016. That grant vested in full on the first anniversary of the grant date or immediately (x) upon a change in control or a hostile takeover of the Company or (y) the death or permanent disability of the grantee if still serving at that time. The original grant was adjusted to 2,034 shares and the exercise price adjusted to $69.51 pursuant to the OmniAb Inc. separation from the Company."}],"balance_after":0,"derivative":{"exercise_price":69.51,"expiration_date":"2026-05-23","underlying":"Common Stock","underlying_shares":2034},"source":{"system":"sec-edgar","filing":"0001104659-26-023943","document":"tm268007-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/886163/000110465926023943/tm268007-1_4seq1.xml","form_type":"4"}},{"id":859682,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":37006,"kind":"person","name":"Sabba Stephen L","position":1,"cik":"0001442372","reported_name":"Sabba Stephen L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-05T16:05:17.000Z","date":"2026-03-03","kind":"sale","planned":false,"acquired":false,"shares":2034,"price":201.5,"value":409851.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These securities, as represented in Column 5, includes the grant of 1,209 restricted shares approved by the Board of Directors of the Company at the Annual Meeting held June 6, 2025, which shares will vest in full on the earlier of (a) the date of the next annual meeting of the Company stockholders following the grant date (such meeting has not yet been held) or (b) on the first anniversary of the grant date, as reported on the Reporting Person's Form 4, dated 10 June 2025, which was filed to reflect the 2025 Meeting grant."}],"balance_after":33793,"source":{"system":"sec-edgar","filing":"0001104659-26-023943","document":"tm268007-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000110465926023943/tm268007-1_4seq1.xml","form_type":"4"}},{"id":859681,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":37006,"kind":"person","name":"Sabba Stephen L","position":1,"cik":"0001442372","reported_name":"Sabba Stephen L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-05T16:05:17.000Z","date":"2026-03-03","kind":"exercise","planned":false,"acquired":true,"shares":2034,"price":69.51,"value":141383.34,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These securities, as represented in Column 5, includes the grant of 1,209 restricted shares approved by the Board of Directors of the Company at the Annual Meeting held June 6, 2025, which shares will vest in full on the earlier of (a) the date of the next annual meeting of the Company stockholders following the grant date (such meeting has not yet been held) or (b) on the first anniversary of the grant date, as reported on the Reporting Person's Form 4, dated 10 June 2025, which was filed to reflect the 2025 Meeting grant."}],"balance_after":35827,"source":{"system":"sec-edgar","filing":"0001104659-26-023943","document":"tm268007-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000110465926023943/tm268007-1_4seq1.xml","form_type":"4"}},{"id":1116956,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":37006,"kind":"person","name":"Sabba Stephen L","position":1,"cik":"0001442372","reported_name":"Sabba Stephen L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2025-06-10T23:21:40.000Z","date":"2025-06-06","kind":"grant","planned":false,"acquired":true,"shares":5783,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 6, 2025. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant."}],"balance_after":5783,"derivative":{"exercise_price":105.99,"expiration_date":"2035-06-06","underlying":"Common Stock","underlying_shares":5783},"source":{"system":"sec-edgar","filing":"0002001011-25-000042","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101125000042/edgardoc.xml","form_type":"4"}},{"id":1116955,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":37006,"kind":"person","name":"Sabba Stephen L","position":1,"cik":"0001442372","reported_name":"Sabba Stephen L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-10T23:21:40.000Z","date":"2025-06-06","kind":"grant","planned":false,"acquired":true,"shares":1209,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 6, 2025. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant."}],"balance_after":33793,"source":{"system":"sec-edgar","filing":"0002001011-25-000042","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101125000042/edgardoc.xml","form_type":"4"}},{"id":1171335,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":37006,"kind":"person","name":"Sabba Stephen L","position":1,"cik":"0001442372","reported_name":"Sabba Stephen L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2025-04-16T13:34:19.000Z","date":"2025-04-01","kind":"exercise","planned":false,"acquired":false,"shares":2406,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"These securities, as represented in Column 5, were acquired by a grant of 2,754 shares approved by the Board of Directors of the Company at the 2015 Meeting, as previously reported on the Reporting Person's Form 4, dated 28 April 2015. That grant vested in full on the first anniversary of the grant date or immediately (x) upon a change in control or a hostile takeover of the Company or (y) the death or permanent disability of the grantee if still serving at that time. The original grant was adjusted to 2,406 shares and the exercise price adjusted to $52.30 pursuant to the OmniAb Inc. separation from the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These securities, as represented in Column 5, were acquired by a grant of 2,754 shares approved by the Board of Directors of the Company at the 2015 Meeting, as previously reported on the Reporting Person's Form 4, dated 28 April 2015. That grant vested in full on the first anniversary of the grant date or immediately (x) upon a change in control or a hostile takeover of the Company or (y) the death or permanent disability of the grantee if still serving at that time. The original grant was adjusted to 2,406 shares and the exercise price adjusted to $52.30 pursuant to the OmniAb Inc. separation from the Company."}],"balance_after":0,"derivative":{"exercise_price":52.3,"expiration_date":"2025-04-24","underlying":"Common Stock","underlying_shares":2406},"source":{"system":"sec-edgar","filing":"0001104659-25-035352","document":"tm2512441-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000110465925035352/tm2512441-1_4seq1.xml","form_type":"4"}},{"id":1171334,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":37006,"kind":"person","name":"Sabba Stephen L","position":1,"cik":"0001442372","reported_name":"Sabba Stephen L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-16T13:34:19.000Z","date":"2025-04-01","kind":"exercise","planned":false,"acquired":true,"shares":2406,"price":52.3,"value":125833.8,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These securities, as represented in Column 5, includes the grant of 1,252 restricted shares approved by the Board of Directors of the Company at the Annual Meeting held June 14, 2024, which shares will vest in full on the earlier of (a) the date of the next annual meeting of the Company stockholders following the grant date (such meeting has not yet been held) or (b) on the first anniversary of the grant date, as reported on the Reporting Person's Form 4, dated 25 June 2024, which was filed to reflect the 2024 Meeting grant."}],"balance_after":32584,"source":{"system":"sec-edgar","filing":"0001104659-25-035352","document":"tm2512441-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000110465925035352/tm2512441-1_4seq1.xml","form_type":"4"}},{"id":1469967,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":37006,"kind":"person","name":"Sabba Stephen L","position":1,"cik":"0001442372","reported_name":"Sabba Stephen L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2024-06-25T23:45:06.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":5444,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 14, 2024. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant."}],"balance_after":5444,"derivative":{"exercise_price":80.06,"expiration_date":"2034-06-14","underlying":"Common Stock","underlying_shares":5444},"source":{"system":"sec-edgar","filing":"0002001011-24-000061","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101124000061/edgardoc.xml","form_type":"4"}},{"id":1469966,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":37006,"kind":"person","name":"Sabba Stephen L","position":1,"cik":"0001442372","reported_name":"Sabba Stephen L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-25T23:45:06.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":1252,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 14, 2024. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant."}],"balance_after":30178,"source":{"system":"sec-edgar","filing":"0002001011-24-000061","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000200101124000061/edgardoc.xml","form_type":"4"}},{"id":1590043,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":37006,"kind":"person","name":"Sabba Stephen L","position":1,"cik":"0001442372","reported_name":"Sabba Stephen L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2024-03-07T18:27:20.000Z","date":"2024-03-05","kind":"exercise","planned":false,"acquired":false,"shares":2893,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"These securities, as represented in Column 5, were acquired by a grant of 3,312 shares by the Board of Directors of the Company at the 2014 Meeting. That grant vested in full on the first anniversary of the grant date or immediately (x) upon a change in control or a hostile takeover of the Company or (y) the death or permanent disability of the grantee if still serving at that time."},{"field":"security","element":"securityTitle","label":"F3","text":"This Option was previously reported on the Form 4 filed 6/6/14 as a Grant of 3,312 shares, which vested in full on April 24, 2015, at an exercise price of $67.53 per share, but was adjusted pursuant to the OmniAb Inc. separation from the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These securities, as represented in Column 5, were acquired by a grant of 3,312 shares by the Board of Directors of the Company at the 2014 Meeting. That grant vested in full on the first anniversary of the grant date or immediately (x) upon a change in control or a hostile takeover of the Company or (y) the death or permanent disability of the grantee if still serving at that time."}],"balance_after":419,"derivative":{"exercise_price":67.53,"expiration_date":"2024-06-04","underlying":"Common Stock","underlying_shares":2893},"source":{"system":"sec-edgar","filing":"0001104659-24-031806","document":"tm248239-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/886163/000110465924031806/tm248239-1_4seq1.xml","form_type":"4"}},{"id":1590042,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":37006,"kind":"person","name":"Sabba Stephen L","position":1,"cik":"0001442372","reported_name":"Sabba Stephen L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-07T18:27:20.000Z","date":"2024-03-05","kind":"sale","planned":false,"acquired":false,"shares":1893,"price":74.3,"value":140649.9,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These securities, as represented in Column 5, include a grant of 1,142 restricted share units approved by the Board of Directors of the Company at the 2023 Meeting, which shares will vest in full on the earlier of (a) the date of the next annual meeting of the Company stockholders following the grant date or (b) on the first anniversary of the grant date. They also properly reflect adjustments from the OmniAb Inc. separation from the Issuer. The Shares referenced in Column 5 of Table I as disposed of on the Form 4 filed 5/10/23 for this Reporting Person inadvertently failed correctly to reflect those adjustments. That number should have been 26,784."}],"balance_after":28926,"source":{"system":"sec-edgar","filing":"0001104659-24-031806","document":"tm248239-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000110465924031806/tm248239-1_4seq1.xml","form_type":"4"}},{"id":1590041,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":37006,"kind":"person","name":"Sabba Stephen L","position":1,"cik":"0001442372","reported_name":"Sabba Stephen L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-07T18:27:20.000Z","date":"2024-03-05","kind":"exercise","planned":false,"acquired":true,"shares":2893,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These securities, as represented in Column 5, include a grant of 1,142 restricted share units approved by the Board of Directors of the Company at the 2023 Meeting, which shares will vest in full on the earlier of (a) the date of the next annual meeting of the Company stockholders following the grant date or (b) on the first anniversary of the grant date. They also properly reflect adjustments from the OmniAb Inc. separation from the Issuer. The Shares referenced in Column 5 of Table I as disposed of on the Form 4 filed 5/10/23 for this Reporting Person inadvertently failed correctly to reflect those adjustments. That number should have been 26,784."}],"balance_after":30819,"source":{"system":"sec-edgar","filing":"0001104659-24-031806","document":"tm248239-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000110465924031806/tm248239-1_4seq1.xml","form_type":"4"}},{"id":1848292,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":37006,"kind":"person","name":"Sabba Stephen L","position":1,"cik":"0001442372","reported_name":"Sabba Stephen L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2023-06-21T13:28:39.000Z","date":"2023-06-09","kind":"grant","planned":false,"acquired":false,"shares":5461,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"These securities, as represented in Column 5, were acquired by a grant of 5,461 shares approved by the Board of Directors of the Company at the 2023 Meeting. That grant (a) vests in full on the earlier of (i) the date of the next annual meeting of the Company stockholders following the grant date or (ii) on the first anniversary of the grant date, and (b) will vest immediately (i) upon a change in control or a hostile takeover of the Company or (ii) the death or permanent disability of the grantee if still serving at that time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These securities, as represented in Column 5, were acquired by a grant of 5,461 shares approved by the Board of Directors of the Company at the 2023 Meeting. That grant (a) vests in full on the earlier of (i) the date of the next annual meeting of the Company stockholders following the grant date or (ii) on the first anniversary of the grant date, and (b) will vest immediately (i) upon a change in control or a hostile takeover of the Company or (ii) the death or permanent disability of the grantee if still serving at that time."}],"balance_after":5461,"derivative":{"exercise_price":73.76,"expiration_date":"2033-06-09","underlying":"Common Stock","underlying_shares":5461},"source":{"system":"sec-edgar","filing":"0001104659-23-073212","document":"tm2319289-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000110465923073212/tm2319289-1_4seq1.xml","form_type":"4"}},{"id":1848291,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":37006,"kind":"person","name":"Sabba Stephen L","position":1,"cik":"0001442372","reported_name":"Sabba Stephen L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-21T13:28:39.000Z","date":"2023-06-09","kind":"grant","planned":false,"acquired":true,"shares":1142,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These securities, as represented in Column 5, include a grant of 1,142 restricted share units approved by the Board of Directors of the Company at the 2023 Meeting, which shares will vest in full on the earlier of (a) the date of the next annual meeting of the Company stockholders following the grant date or (b) on the first anniversary of the grant date."}],"balance_after":26926,"source":{"system":"sec-edgar","filing":"0001104659-23-073212","document":"tm2319289-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000110465923073212/tm2319289-1_4seq1.xml","form_type":"4"}},{"id":1895764,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":37006,"kind":"person","name":"Sabba Stephen L","position":1,"cik":"0001442372","reported_name":"Sabba Stephen L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2023-05-12T19:43:24.000Z","date":"2023-05-10","kind":"exercise","planned":false,"acquired":false,"shares":6408,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"These securities, as represented in Column 5, were acquired by a grant of 7,335 shares approved by the Board of Directors of the Company at the 2013 Meeting, as previously reported on the Reporting Persons Form 4 dated 13 June 2013. That grant vested in full on the first anniversary of the grant date or immediately (x) upon a change in control or a hostile takeover of the Company or (y) the death or permanent disability of the grantee if still serving at that time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These securities, as represented in Column 5, were acquired by a grant of 7,335 shares approved by the Board of Directors of the Company at the 2013 Meeting, as previously reported on the Reporting Persons Form 4 dated 13 June 2013. That grant vested in full on the first anniversary of the grant date or immediately (x) upon a change in control or a hostile takeover of the Company or (y) the death or permanent disability of the grantee if still serving at that time."}],"balance_after":927,"derivative":{"exercise_price":18.82,"expiration_date":"2023-06-11","underlying":"Common Stock","underlying_shares":6408},"source":{"system":"sec-edgar","filing":"0001104659-23-059680","document":"tm2315666-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/886163/000110465923059680/tm2315666-1_4seq1.xml","form_type":"4"}},{"id":1895763,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":37006,"kind":"person","name":"Sabba Stephen L","position":1,"cik":"0001442372","reported_name":"Sabba Stephen L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-12T19:43:24.000Z","date":"2023-05-10","kind":"sale","planned":false,"acquired":false,"shares":6408,"price":77.1262,"value":494224.6896,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These securities, as represented in Column 5, include a grant of 1,723 restricted shares approved by the Board of Directors of the Company at the 2022 Meeting (\"2022 Shares\"), which shares will vest in full on the earlier of (a) the date of the next annual meeting of the Company stockholders following the grant date or (b) on the first anniversary of the grant date. As reported on the Reporting Person's Form 4 dated 14 June 2022, which was filed to reflect the 2022 Meeting grant, the original grant was for 1,004 2022 Shares. The reference to 1,732 2022 Shares reflects certain adjustments by the Company to the 2022 Shares following the Company's 1 November 2022 distribution of a legacy business."},{"field":"security","element":"securityTitle","label":"F2","text":"The price reported in Column 4 is an average. These shares were sold in separate transactions for the following number of shares and at the respective prices: $77.29 (100), $77.25 (8), $77.23 (41), $77.22 (36), $77.21 (201), $77.20 (372), $77.18 (800), $77.17 (120), $77.16 (34), $77.15 (971), $77.14 (1,305), $77.13 (151), $77.12 (1), $77.11 (239), $77.10 (101), $77.09 (100), $77.08 (1,065), $77.01 (9), and $77.00 (754). This disposition was reported on a Form 144 for filed 10 May 2023."}],"balance_after":25784,"source":{"system":"sec-edgar","filing":"0001104659-23-059680","document":"tm2315666-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000110465923059680/tm2315666-1_4seq1.xml","form_type":"4"}},{"id":1895762,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":37006,"kind":"person","name":"Sabba Stephen L","position":1,"cik":"0001442372","reported_name":"Sabba Stephen L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-12T19:43:24.000Z","date":"2023-05-10","kind":"exercise","planned":false,"acquired":true,"shares":6408,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These securities, as represented in Column 5, include a grant of 1,723 restricted shares approved by the Board of Directors of the Company at the 2022 Meeting (\"2022 Shares\"), which shares will vest in full on the earlier of (a) the date of the next annual meeting of the Company stockholders following the grant date or (b) on the first anniversary of the grant date. As reported on the Reporting Person's Form 4 dated 14 June 2022, which was filed to reflect the 2022 Meeting grant, the original grant was for 1,004 2022 Shares. The reference to 1,732 2022 Shares reflects certain adjustments by the Company to the 2022 Shares following the Company's 1 November 2022 distribution of a legacy business."}],"balance_after":32192,"source":{"system":"sec-edgar","filing":"0001104659-23-059680","document":"tm2315666-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000110465923059680/tm2315666-1_4seq1.xml","form_type":"4"}},{"id":2076333,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":37006,"kind":"person","name":"Sabba Stephen L","position":1,"cik":"0001442372","reported_name":"Sabba Stephen L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-12-27T23:30:11.000Z","date":"2022-12-22","kind":"grant","acquired":true,"shares":6623,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Grant to reporting person of stock options that will vest and become exercisable on December 22, 2023."}],"balance_after":6623,"derivative":{"exercise_price":67.03,"expiration_date":"2032-12-22","underlying":"Common Stock","underlying_shares":6623},"source":{"system":"sec-edgar","filing":"0000899243-22-039408","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000089924322039408/doc4.xml","form_type":"4"}},{"id":2233315,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":37006,"kind":"person","name":"Sabba Stephen L","position":1,"cik":"0001442372","reported_name":"Sabba Stephen L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-06-14T19:56:14.000Z","date":"2022-06-10","kind":"grant","acquired":false,"shares":4340,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"These securities, as represented in Column 5, were acquired by a grant of 4,340 shares approved by the Board of Directors of the Company at the 2022 Meeting. That grant (a) vests in full on the earlier of (i) the date of the next annual meeting of the Company stockholders following the grant date or (ii) on the first anniversary of the grant date, and (b) will vest immediately (i) upon a change in control or a hostile takeover of the Company or (ii) the death or permanent disability of the grantee if still serving at that time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These securities, as represented in Column 5, were acquired by a grant of 4,340 shares approved by the Board of Directors of the Company at the 2022 Meeting. That grant (a) vests in full on the earlier of (i) the date of the next annual meeting of the Company stockholders following the grant date or (ii) on the first anniversary of the grant date, and (b) will vest immediately (i) upon a change in control or a hostile takeover of the Company or (ii) the death or permanent disability of the grantee if still serving at that time."}],"balance_after":4340,"derivative":{"exercise_price":79.29,"expiration_date":"2032-06-10","underlying":"Common Stock","underlying_shares":4340},"source":{"system":"sec-edgar","filing":"0001104659-22-070992","document":"tm2218418-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000110465922070992/tm2218418-1_4seq1.xml","form_type":"4"}},{"id":2233314,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":37006,"kind":"person","name":"Sabba Stephen L","position":1,"cik":"0001442372","reported_name":"Sabba Stephen L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-14T19:56:14.000Z","date":"2022-06-10","kind":"grant","acquired":true,"shares":1004,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These securities, as represented in Column 5, include a grant of 1,004 restricted share units approved by the Board of Directors of the Company at the 2022 Meeting, which shares will vest in full on the earlier of (a) the date of the next annual meeting of the Company stockholders following the grant date or (b) on the first anniversary of the grant date."}],"balance_after":26065,"source":{"system":"sec-edgar","filing":"0001104659-22-070992","document":"tm2218418-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000110465922070992/tm2218418-1_4seq1.xml","form_type":"4"}},{"id":2678328,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":37006,"kind":"person","name":"Sabba Stephen L","position":1,"cik":"0001442372","reported_name":"Sabba Stephen L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2021-06-08T18:26:24.000Z","date":"2021-06-04","kind":"grant","acquired":false,"shares":3269,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"These securities, as represented in Column 5, were acquired by a grant of 3,269 shares approved by the Board of Directors of the Company at the 2021 Meeting. That grant (a) vests in full on the earlier of (i) the date of the next annual meeting of the Company stockholders following the grant date or (ii) on the first anniversary of the grant date, and (b) will vest immediately (i) upon a change in control or a hostile takeover of the Company or (ii) the death or permanent disability of the grantee if still serving at that time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These securities, as represented in Column 5, were acquired by a grant of 3,269 shares approved by the Board of Directors of the Company at the 2021 Meeting. That grant (a) vests in full on the earlier of (i) the date of the next annual meeting of the Company stockholders following the grant date or (ii) on the first anniversary of the grant date, and (b) will vest immediately (i) upon a change in control or a hostile takeover of the Company or (ii) the death or permanent disability of the grantee if still serving at that time."}],"balance_after":3269,"derivative":{"exercise_price":115.39,"expiration_date":"2031-06-04","underlying":"Common Stock","underlying_shares":3269},"source":{"system":"sec-edgar","filing":"0001104659-21-078158","document":"tm2119120-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000110465921078158/tm2119120-1_4seq1.xml","form_type":"4"}},{"id":2678327,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":37006,"kind":"person","name":"Sabba Stephen L","position":1,"cik":"0001442372","reported_name":"Sabba Stephen L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-08T18:26:24.000Z","date":"2021-06-04","kind":"grant","acquired":true,"shares":630,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These securities, as represented in Column 5, include a grant of 630 restricted shares approved by the Board of Directors of the Company at the 2021 Meeting, which shares will vest in full on the earlier of (a) the date of the next annual meeting of the Company stockholders following the grant date or (b) on the first anniversary of the grant date."}],"balance_after":25061,"source":{"system":"sec-edgar","filing":"0001104659-21-078158","document":"tm2119120-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000110465921078158/tm2119120-1_4seq1.xml","form_type":"4"}},{"id":2867562,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":37006,"kind":"person","name":"Sabba Stephen L","position":1,"cik":"0001442372","reported_name":"Sabba Stephen L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2021-02-11T21:06:15.000Z","date":"2021-02-09","kind":"exercise","acquired":false,"shares":7335,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"These securities, as represented in Column 5, were acquired by a grant of 7,335 shares approved by the Board of Directors of the Company at the 2012 Meeting and are fully vested and exerciseable as more fully described on a Form 4 for this Reporting Person filed on June 4, 2012."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These securities, as represented in Column 5, were acquired by a grant of 7,335 shares approved by the Board of Directors of the Company at the 2012 Meeting and are fully vested and exerciseable as more fully described on a Form 4 for this Reporting Person filed on June 4, 2012."}],"balance_after":0,"derivative":{"exercise_price":12.53,"expiration_date":"2022-05-31","underlying":"Common Stock","underlying_shares":7335},"source":{"system":"sec-edgar","filing":"0001104659-21-020672","document":"tm216285-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/886163/000110465921020672/tm216285-1_4seq1.xml","form_type":"4"}},{"id":2867561,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":37006,"kind":"person","name":"Sabba Stephen L","position":1,"cik":"0001442372","reported_name":"Sabba Stephen L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2021-02-11T21:06:15.000Z","date":"2021-02-09","kind":"exercise","acquired":false,"shares":7335,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"These securities, as represented in Column 5, were acquired by a grant of 7,335 shares approved by the Board of Directors of the Company at the 2011 Meeting and are fully vested and exerciseable as more fully described on a Form 4 for this Reporting Person filed on June 6, 2011."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These securities, as represented in Column 5, were acquired by a grant of 7,335 shares approved by the Board of Directors of the Company at the 2011 Meeting and are fully vested and exerciseable as more fully described on a Form 4 for this Reporting Person filed on June 6, 2011."}],"balance_after":0,"derivative":{"exercise_price":10.12,"expiration_date":"2021-06-01","underlying":"Common Stock","underlying_shares":7335},"source":{"system":"sec-edgar","filing":"0001104659-21-020672","document":"tm216285-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/886163/000110465921020672/tm216285-1_4seq1.xml","form_type":"4"}},{"id":2867560,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":37006,"kind":"person","name":"Sabba Stephen L","position":1,"cik":"0001442372","reported_name":"Sabba Stephen L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-11T21:06:15.000Z","date":"2021-02-09","kind":"sale","acquired":false,"shares":14114,"price":208.55,"value":2943474.7,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These securities, as represented in Column 5, include a grant of 831 restricted shares approved by the Board of Directors of the Company at the 2020 Meeting, which shares were previously reported on a Form 4 for this Reporting Person filed on June 12, 2020, and are included on this Form 4 only to report that they will vest in full within six (6) months from the date hereof."}],"balance_after":24431,"source":{"system":"sec-edgar","filing":"0001104659-21-020672","document":"tm216285-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/886163/000110465921020672/tm216285-1_4seq1.xml","form_type":"4"}},{"id":2867559,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":37006,"kind":"person","name":"Sabba Stephen L","position":1,"cik":"0001442372","reported_name":"Sabba Stephen L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-11T21:06:15.000Z","date":"2021-02-09","kind":"sale","acquired":false,"shares":556,"price":208,"value":115648.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These securities, as represented in Column 5, include a grant of 831 restricted shares approved by the Board of Directors of the Company at the 2020 Meeting, which shares were previously reported on a Form 4 for this Reporting Person filed on June 12, 2020, and are included on this Form 4 only to report that they will vest in full within six (6) months from the date hereof."}],"balance_after":38545,"source":{"system":"sec-edgar","filing":"0001104659-21-020672","document":"tm216285-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/886163/000110465921020672/tm216285-1_4seq1.xml","form_type":"4"}},{"id":2867558,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":37006,"kind":"person","name":"Sabba Stephen L","position":1,"cik":"0001442372","reported_name":"Sabba Stephen L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-11T21:06:15.000Z","date":"2021-02-09","kind":"exercise","acquired":true,"shares":7335,"price":12.53,"value":91907.55,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These securities, as represented in Column 5, include a grant of 831 restricted shares approved by the Board of Directors of the Company at the 2020 Meeting, which shares were previously reported on a Form 4 for this Reporting Person filed on June 12, 2020, and are included on this Form 4 only to report that they will vest in full within six (6) months from the date hereof."}],"balance_after":39101,"source":{"system":"sec-edgar","filing":"0001104659-21-020672","document":"tm216285-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000110465921020672/tm216285-1_4seq1.xml","form_type":"4"}},{"id":2867557,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":37006,"kind":"person","name":"Sabba Stephen L","position":1,"cik":"0001442372","reported_name":"Sabba Stephen L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-11T21:06:15.000Z","date":"2021-02-09","kind":"exercise","acquired":true,"shares":7335,"price":10.12,"value":74230.2,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These securities, as represented in Column 5, include a grant of 831 restricted shares approved by the Board of Directors of the Company at the 2020 Meeting, which shares were previously reported on a Form 4 for this Reporting Person filed on June 12, 2020, and are included on this Form 4 only to report that they will vest in full within six (6) months from the date hereof."}],"balance_after":31766,"source":{"system":"sec-edgar","filing":"0001104659-21-020672","document":"tm216285-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000110465921020672/tm216285-1_4seq1.xml","form_type":"4"}},{"id":3112451,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":37006,"kind":"person","name":"Sabba Stephen L","position":1,"cik":"0001442372","reported_name":"Sabba Stephen L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2020-06-12T22:46:44.000Z","date":"2020-06-10","kind":"grant","acquired":true,"shares":2468,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"These securities, as represented in Column 5, were acquired by a grant of 2,468 shares approved by the Board of Directors of the Company at the 2020 Meeting. That grant (a) vests in full on the earlier of (i) the date of the next annual meeting of the Company stockholders following the grant date or (ii) on the first anniversary of the grant date, and (b) will vest immediately (i) upon a change in control or a hostile takeover of the Company or (ii) the death or permanent disability of the grantee if still serving at that time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These securities, as represented in Column 5, were acquired by a grant of 2,468 shares approved by the Board of Directors of the Company at the 2020 Meeting. That grant (a) vests in full on the earlier of (i) the date of the next annual meeting of the Company stockholders following the grant date or (ii) on the first anniversary of the grant date, and (b) will vest immediately (i) upon a change in control or a hostile takeover of the Company or (ii) the death or permanent disability of the grantee if still serving at that time."}],"balance_after":2468,"derivative":{"exercise_price":117.58,"expiration_date":"2030-06-10","underlying":"Common Stock","underlying_shares":2468},"source":{"system":"sec-edgar","filing":"0001104659-20-073020","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000110465920073020/a4.xml","form_type":"4"}},{"id":3112450,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":37006,"kind":"person","name":"Sabba Stephen L","position":1,"cik":"0001442372","reported_name":"Sabba Stephen L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-12T22:46:44.000Z","date":"2020-06-10","kind":"grant","acquired":true,"shares":831,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These securities, as represented in Column 5, include a grant of 831 restricted shares approved by the Board of Directors of the Company at the 2020 Meeting, which shares will vest in full on the earlier of (a) the date of the next annual meeting of the Company stockholders following the grant date or (b) on the first anniversary of the grant date."}],"balance_after":24431,"source":{"system":"sec-edgar","filing":"0001104659-20-073020","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000110465920073020/a4.xml","form_type":"4"}},{"id":3451386,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":37006,"kind":"person","name":"Sabba Stephen L","position":1,"cik":"0001442372","reported_name":"Sabba Stephen L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-08-01T18:49:49.000Z","date":"2019-07-31","kind":"sale","acquired":false,"shares":4091,"price":94.45,"value":386394.95,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These securities, as represented in Column 5, include restricted shares comprised of: (a) a grant of 835 restricted shares in a transaction exempt from Section 16b treatment, as originally reported on a Form 4 filed June 10, 2019, which shares will vest in full on the earlier of (i) the date of the next annual meeting of the Company stockholders following the grant date or (ii) on the first anniversary of the grant date; and (b) fully vested restricted shares granted in respective transactions, each exempt from Section 16b treatment and reported on previously filed Form 4s for the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is based on an average share price from the following transactions: ((767 shares @ $96.0691)+(100 shares @ $95.605)+(600 shares @ $95.438334)+(2,624 shares @ $93.70))/ 4,091 shares. The price reported has been rounded from $94.4456857 for formatting purposes."}],"balance_after":23600,"source":{"system":"sec-edgar","filing":"0001104659-19-043306","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000110465919043306/a4.xml","form_type":"4"}},{"id":3496354,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":37006,"kind":"person","name":"Sabba Stephen L","position":1,"cik":"0001442372","reported_name":"Sabba Stephen L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2019-06-10T16:15:14.000Z","date":"2019-06-06","kind":"grant","acquired":true,"shares":4071,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"These securities, as represented in Column 5, were acquired by a grant of 4,071 shares approved by the Board of Directors of the Company at the 2019 Meeting. That grant (a) vests in full on the earlier of (i) the date of the next annual meeting of the Company stockholders following the grant date or (ii) on the first anniversary of the grant date, and (b) will vest immediately (i) upon a change in control or a hostile takeover of the Company or (ii) the death or permanent disability of the grantee if still serving at that time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These securities, as represented in Column 5, were acquired by a grant of 4,071 shares approved by the Board of Directors of the Company at the 2019 Meeting. That grant (a) vests in full on the earlier of (i) the date of the next annual meeting of the Company stockholders following the grant date or (ii) on the first anniversary of the grant date, and (b) will vest immediately (i) upon a change in control or a hostile takeover of the Company or (ii) the death or permanent disability of the grantee if still serving at that time."}],"balance_after":4071,"derivative":{"exercise_price":113.59,"expiration_date":"2029-06-06","underlying":"Common Stock","underlying_shares":4071},"source":{"system":"sec-edgar","filing":"0001104659-19-034623","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000110465919034623/a4.xml","form_type":"4"}},{"id":3496353,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":37006,"kind":"person","name":"Sabba Stephen L","position":1,"cik":"0001442372","reported_name":"Sabba Stephen L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-10T16:15:14.000Z","date":"2019-06-06","kind":"grant","acquired":true,"shares":835,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These securities, as represented in Column 5, include a grant of 835 restricted shares approved by the Board of Directors of the Company at the 2019 Meeting, which shares will vest in full on the earlier of (a) the date of the next annual meeting of the Company stockholders following the grant date or (b) on the first anniversary of the grant date."}],"balance_after":27691,"source":{"system":"sec-edgar","filing":"0001104659-19-034623","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000110465919034623/a4.xml","form_type":"4"}},{"id":3824357,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":37006,"kind":"person","name":"Sabba Stephen L","position":1,"cik":"0001442372","reported_name":"Sabba Stephen L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2018-09-06T14:40:26.000Z","date":"2018-09-04","kind":"exercise","acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"These securities, as represented in Table II, were acquired in transactions exempt from 16b treatment: the options in the first row were originally granted on May 25, 2010 and those in the second row were originally granted on May 29, 2009 (as both were reported, at their respective exercise prices in Column 2 following the Company's stock split, on a Form 4 filed June 6, 2011)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"These securities are currently fully vested and exercisable, having vested in twelve successive equal monthly installments upon completion of each calendar month of service beginning as follows: for those on the first row of Table II, on May 25, 2010, and for those on the second row of Table II, on May 29, 2009."}],"balance_after":0,"derivative":{"exercise_price":17.88,"expiration_date":"2019-05-29","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001104659-18-055509","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/886163/000110465918055509/a4.xml","form_type":"4"}},{"id":3824356,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":37006,"kind":"person","name":"Sabba Stephen L","position":1,"cik":"0001442372","reported_name":"Sabba Stephen L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2018-09-06T14:40:26.000Z","date":"2018-09-04","kind":"exercise","acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"These securities, as represented in Table II, were acquired in transactions exempt from 16b treatment: the options in the first row were originally granted on May 25, 2010 and those in the second row were originally granted on May 29, 2009 (as both were reported, at their respective exercise prices in Column 2 following the Company's stock split, on a Form 4 filed June 6, 2011)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"These securities are currently fully vested and exercisable, having vested in twelve successive equal monthly installments upon completion of each calendar month of service beginning as follows: for those on the first row of Table II, on May 25, 2010, and for those on the second row of Table II, on May 29, 2009."}],"balance_after":0,"derivative":{"exercise_price":8.58,"expiration_date":"2020-05-25","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001104659-18-055509","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/886163/000110465918055509/a4.xml","form_type":"4"}},{"id":3824355,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":37006,"kind":"person","name":"Sabba Stephen L","position":1,"cik":"0001442372","reported_name":"Sabba Stephen L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-09-06T14:40:26.000Z","date":"2018-09-04","kind":"sale","acquired":false,"shares":5000,"price":255.05,"value":1275250.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"These securities, as represented in Column 5, include a grant of 493 restricted shares in a transaction exempt from Section 16b treatment, as originally reported on a Form 4 filed June 21, 2018, which shares will vest in full on the earlier of (a) the date of the next annual meeting of the Company stockholders following the grant date or (b) on the first anniversary of the grant date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is based on an average share price from the following transactions: ((100 shares @ $255.64)+(100 shares @ $255.46)+(200 shares @ $255.45)+(200 shares @ $255.26)+(106 shares @ $255.16)+(4,294 shares @ $255.00))/5,000 shares. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares and the sale prices for each of the foregoing transactions."}],"balance_after":26856,"source":{"system":"sec-edgar","filing":"0001104659-18-055509","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/886163/000110465918055509/a4.xml","form_type":"4"}},{"id":3824354,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":37006,"kind":"person","name":"Sabba Stephen L","position":1,"cik":"0001442372","reported_name":"Sabba Stephen L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-09-06T14:40:26.000Z","date":"2018-09-04","kind":"exercise","acquired":true,"shares":2500,"price":17.88,"value":44700.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Reporting Person acquired these securities, as represented in Column 4, upon exercise of the options and at their respective per share exercise price reported on Table II, as follows: for the first row on Table I, at an exercise price of $8.58/option set forth on the first row on Table II, and for the second row on Table I, at an exercise price of $17.88/option set forth on the second row on Table II."},{"field":"security","element":"securityTitle","label":"F2","text":"These securities, as represented in Column 5, include a grant of 493 restricted shares in a transaction exempt from Section 16b treatment, as originally reported on a Form 4 filed June 21, 2018, which shares will vest in full on the earlier of (a) the date of the next annual meeting of the Company stockholders following the grant date or (b) on the first anniversary of the grant date."}],"balance_after":31856,"source":{"system":"sec-edgar","filing":"0001104659-18-055509","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000110465918055509/a4.xml","form_type":"4"}},{"id":3824353,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":37006,"kind":"person","name":"Sabba Stephen L","position":1,"cik":"0001442372","reported_name":"Sabba Stephen L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-09-06T14:40:26.000Z","date":"2018-09-04","kind":"exercise","acquired":true,"shares":2500,"price":8.58,"value":21450.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Reporting Person acquired these securities, as represented in Column 4, upon exercise of the options and at their respective per share exercise price reported on Table II, as follows: for the first row on Table I, at an exercise price of $8.58/option set forth on the first row on Table II, and for the second row on Table I, at an exercise price of $17.88/option set forth on the second row on Table II."},{"field":"security","element":"securityTitle","label":"F2","text":"These securities, as represented in Column 5, include a grant of 493 restricted shares in a transaction exempt from Section 16b treatment, as originally reported on a Form 4 filed June 21, 2018, which shares will vest in full on the earlier of (a) the date of the next annual meeting of the Company stockholders following the grant date or (b) on the first anniversary of the grant date."}],"balance_after":29356,"source":{"system":"sec-edgar","filing":"0001104659-18-055509","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000110465918055509/a4.xml","form_type":"4"}},{"id":3846603,"issuer":{"id":152369,"kind":"organization","name":"NOVELION THERAPEUTICS INC.","symbol":"NVLNF"},"owners":[{"id":37006,"kind":"person","name":"Sabba Stephen L","position":1,"cik":"0001442372","reported_name":"Sabba Stephen L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-08-13T16:31:05.000Z","date":"2018-08-09","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each option has an exercise price equal to the closing price of a common share of the Issuer on the Nasdaq Global Select Market on the grant date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest in twelve equal monthly installments, beginning one month after the grant date."}],"balance_after":10000,"derivative":{"exercise_price":3.33,"expiration_date":"2028-08-09","underlying":"Common Shares","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001104659-18-051505","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/827809/000110465918051505/a4.xml","form_type":"4"}},{"id":3876961,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":37006,"kind":"person","name":"Sabba Stephen L","position":1,"cik":"0001442372","reported_name":"Sabba Stephen L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2018-07-03T21:05:29.000Z","date":"2018-06-19","kind":"grant","acquired":true,"shares":2474,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"These securities, as represented in Column 5, were acquired by a grant of 2,474 shares approved by the Board of Directors of the Company at the 2018 Meeting. That grant (a) vests in full on the earlier of (i) the date of the next annual meeting of the Company stockholders following the grant date or (ii) on the first anniversary of the grant date, and (b) will vest immediately (i) upon a change in control or a hostile takeover of the Company or (ii) the death or permanent disability of the grantee if still serving at that time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These securities, as represented in Column 5, were acquired by a grant of 2,474 shares approved by the Board of Directors of the Company at the 2018 Meeting. That grant (a) vests in full on the earlier of (i) the date of the next annual meeting of the Company stockholders following the grant date or (ii) on the first anniversary of the grant date, and (b) will vest immediately (i) upon a change in control or a hostile takeover of the Company or (ii) the death or permanent disability of the grantee if still serving at that time."}],"balance_after":2474,"derivative":{"exercise_price":195.91,"expiration_date":"2028-06-19","underlying":"Common Stock","underlying_shares":2474},"source":{"system":"sec-edgar","filing":"0001104659-18-043872","document":"a4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000110465918043872/a4a.xml","form_type":"4/A","original_submission_date":"2018-06-21"}},{"id":3876960,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":37006,"kind":"person","name":"Sabba Stephen L","position":1,"cik":"0001442372","reported_name":"Sabba Stephen L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-07-03T21:05:29.000Z","date":"2018-06-19","kind":"grant","acquired":true,"shares":493,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These securities, as represented in Column 5, include a grant of 493 restricted shares approved by the Board of Directors of the Company at the 2018 Meeting, which shares will vest in full on the earlier of (a) the date of the next annual meeting of the Company stockholders following the grant date or (b) on the first anniversary of the grant date."}],"balance_after":26856,"source":{"system":"sec-edgar","filing":"0001104659-18-043872","document":"a4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000110465918043872/a4a.xml","form_type":"4/A","original_submission_date":"2018-06-21"}},{"id":3886502,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":37006,"kind":"person","name":"Sabba Stephen L","position":1,"cik":"0001442372","reported_name":"Sabba Stephen L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2018-06-21T16:32:06.000Z","date":"2018-06-19","kind":"grant","acquired":true,"shares":2474,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"These securities, as represented in Column 5, were acquired by a grant of 2,474 shares approved by the Board of Directors of the Company at the 2018 Meeting. That grant (a) vests in full on the earlier of (i) the date of the next annual meeting of the Company stockholders following the grant date or (ii) on the first anniversary of the grant date, and (b) will vest immediately (i) upon a change in control or a hostile takeover of the Company or (ii) the death or permanent disability of the grantee if still serving at that time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These securities, as represented in Column 5, were acquired by a grant of 2,474 shares approved by the Board of Directors of the Company at the 2018 Meeting. That grant (a) vests in full on the earlier of (i) the date of the next annual meeting of the Company stockholders following the grant date or (ii) on the first anniversary of the grant date, and (b) will vest immediately (i) upon a change in control or a hostile takeover of the Company or (ii) the death or permanent disability of the grantee if still serving at that time."}],"balance_after":2474,"derivative":{"exercise_price":76.77,"expiration_date":"2028-06-19","underlying":"Common Stock","underlying_shares":2474},"source":{"system":"sec-edgar","filing":"0001104659-18-041511","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000110465918041511/a4.xml","form_type":"4"}},{"id":3886501,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":37006,"kind":"person","name":"Sabba Stephen L","position":1,"cik":"0001442372","reported_name":"Sabba Stephen L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-21T16:32:06.000Z","date":"2018-06-19","kind":"grant","acquired":true,"shares":493,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These securities, as represented in Column 5, include a grant of 493 restricted shares approved by the Board of Directors of the Company at the 2018 Meeting, which shares will vest in full on the earlier of (a) the date of the next annual meeting of the Company stockholders following the grant date or (b) on the first anniversary of the grant date."}],"balance_after":26856,"source":{"system":"sec-edgar","filing":"0001104659-18-041511","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000110465918041511/a4.xml","form_type":"4"}},{"id":3999468,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":37006,"kind":"person","name":"Sabba Stephen L","position":1,"cik":"0001442372","reported_name":"Sabba Stephen L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-03-13T22:15:40.000Z","date":"2018-03-12","kind":"sale","acquired":false,"shares":622,"price":180.73,"value":112414.06,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These securities, as represented in Column 5, include a grant of 666 restricted shares approved by the Board of Directors of the Company at the 2017 Meeting, which shares will vest in full on the earlier of (a) the date of the next annual meeting of the Company stockholders following the grant date or (b) on the first anniversary of the grant date."}],"balance_after":26363,"source":{"system":"sec-edgar","filing":"0001104659-18-017201","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000110465918017201/a4.xml","form_type":"4"}},{"id":4124335,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":37006,"kind":"person","name":"Sabba Stephen L","position":1,"cik":"0001442372","reported_name":"Sabba Stephen L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-12-21T11:31:38.000Z","date":"2017-12-20","kind":"sale","acquired":false,"shares":925,"price":137.25,"value":126956.25,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These securities, as represented in Column 5 and as previously reported in the Form 4 filed for this Reporting Person on May 30, 2017, include a grant of 666 restricted shares approved by the Board of Directors of the Company at the 2017 Meeting, which shares will vest in full on the earlier of (a) the date of the next annual meeting of the Company stockholders following the grant date or (b) on the first anniversary of the grant date."}],"balance_after":26985,"source":{"system":"sec-edgar","filing":"0001104659-17-074431","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000110465917074431/a4.xml","form_type":"4"}},{"id":4301938,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":37006,"kind":"person","name":"Sabba Stephen L","position":1,"cik":"0001442372","reported_name":"Sabba Stephen L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2017-05-30T16:02:48.000Z","date":"2017-05-25","kind":"grant","acquired":true,"shares":2456,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"These securities, as represented in Column 5, were acquired by a grant of 2,456 shares approved by the Board of Directors of the Company at the 2017 Meeting. That grant (a) vests in full on the earlier of (i) the date of the next annual meeting of the Company stockholders following the grant date or (ii) on the first anniversary of the grant date, and (b) will vest immediately (i) upon a change in control or a hostile takeover of the Company or (ii) the death or permanent disability of the grantee if still serving at that time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These securities, as represented in Column 5, were acquired by a grant of 2,456 shares approved by the Board of Directors of the Company at the 2017 Meeting. That grant (a) vests in full on the earlier of (i) the date of the next annual meeting of the Company stockholders following the grant date or (ii) on the first anniversary of the grant date, and (b) will vest immediately (i) upon a change in control or a hostile takeover of the Company or (ii) the death or permanent disability of the grantee if still serving at that time."}],"balance_after":2456,"derivative":{"exercise_price":113.5,"expiration_date":"2027-05-25","underlying":"Common Stock","underlying_shares":2456},"source":{"system":"sec-edgar","filing":"0001104659-17-035988","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/886163/000110465917035988/a4.xml","form_type":"4"}},{"id":4301937,"issuer":{"id":3825,"kind":"organization","name":"LIGAND PHARMACEUTICALS INC","symbol":"LGND"},"owners":[{"id":37006,"kind":"person","name":"Sabba Stephen L","position":1,"cik":"0001442372","reported_name":"Sabba Stephen L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-05-30T16:02:48.000Z","date":"2017-05-25","kind":"grant","acquired":true,"shares":666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These securities, as represented in Column 5, include a grant of 666 restricted shares approved by the Board of Directors of the Company at the 2017 Meeting, which shares will vest in full on the earlier of (a) the date of the next annual meeting of the Company stockholders following the grant date or (b) on the first anniversary of the grant date."}],"balance_after":27910,"source":{"system":"sec-edgar","filing":"0001104659-17-035988","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/886163/000110465917035988/a4.xml","form_type":"4"}},{"id":4512189,"issuer":{"id":152369,"kind":"organization","name":"NOVELION THERAPEUTICS INC.","symbol":"NVLNF"},"owners":[{"id":37006,"kind":"person","name":"Sabba Stephen L","position":1,"cik":"0001442372","reported_name":"Sabba Stephen L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2016-12-27T16:11:48.000Z","date":"2016-12-22","kind":"grant","acquired":true,"shares":9600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each option has an exercise price equal to the closing price of a common share of the Issuer on the Nasdaq Global Select Market on the grant date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The common shares underlying this stock option award will vest in equal monthly installments over 36 months, beginning one month after the grant date."}],"balance_after":9600,"derivative":{"exercise_price":8.65,"expiration_date":"2026-12-22","underlying":"Common Shares","underlying_shares":9600},"source":{"system":"sec-edgar","filing":"0001104659-16-163886","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/827809/000110465916163886/a4.xml","form_type":"4"}}]}